LB Pharmaceuticals Files for IPO

Dow Jones

Aug 23

By Kelly Cloonan

LB Pharmaceuticals has filed for an initial public offering.

The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday.

The company didn't disclose the expected price or size of the offering.

LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters.

The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression.

The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

August 22, 2025 17:28 ET (21:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2561834532"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561834532\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561834532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-23 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561834532","market":"hk","top_or_hot":-1,"title":"LB Pharmaceuticals Files for IPO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LB Pharmaceuticals has filed for an initial public offering. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n</p>\n<p>\n  The company didn't disclose the expected price or size of the offering. \n</p>\n<p>\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and <a href=\"https://laohu8.com/S/SFB\">Stifel</a> are listed as the offering's underwriters. \n</p>\n<p>\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n</p>\n<p>\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 22, 2025 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LB Pharmaceuticals Files for IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLB Pharmaceuticals Files for IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-23 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LB Pharmaceuticals has filed for an initial public offering. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n</p>\n<p>\n  The company didn't disclose the expected price or size of the offering. \n</p>\n<p>\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and <a href=\"https://laohu8.com/S/SFB\">Stifel</a> are listed as the offering's underwriters. \n</p>\n<p>\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n</p>\n<p>\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 22, 2025 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4213","symbol_name":"石油与天然气的勘探与生产","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2561834532","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561834532","pubTimestamp":1755898080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"LB Pharmaceuticals has filed for an initial public offering.The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday.The company didn't disclose the expected price or size of the offering.LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters.The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression.The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4213":"石油与天然气的勘探与生产","BK4233":"房地产运营公司","LB":"LandBridge Co. LLC"},"translate_title":"LB制药申请首次公开募股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LB":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  LB Pharmaceuticals has filed for an initial public offering. \n\n\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n\n\n  The company didn't disclose the expected price or size of the offering. \n\n\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters. \n\n\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n\n\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 22, 2025 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}